| Autor: |
Akhmadeeva, G. N., Magzhanov, R. V., Tayupova, G. N., Baitimerov, A. R., Khidiyatova, I. M. |
| Předmět: |
|
| Zdroj: |
Neuroscience & Behavioral Physiology; Jun2018, Vol. 48 Issue 5, p636-640, 5p |
| Abstrakt: |
This review presents data from recent studies throughout the world on anxious-depressive disorders in patients with Parkinson’s disease (PD); their features and epidemiology are presented, along with details of pathogenesis, clinical properties, and contemporary diagnostic and therapeutic methods. Depression is encountered in an average of 40-50% of patients with PD and anxiety in 17-43%. Only one medication -pramipexole (a dopamine receptor agonist) - is recommended for the treatment of depression. Two more, nortriptyline and desipramine, which are tricyclic antidepressants, are “probably” effective. There are as yet no clear recommendations for the treatment of anxiety. Overall, methods for the treatment of anxious/depressive disorder in PD have received insufficient study, suggesting the need for future large-scale studies. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink